PharmaSources E-Newsletter November 2022 Issue 1

[PharmaSources]

View this E-mail (https://info.cphi-chinaedm.com/x/?S7Y1Mf2fa2tsYG5p8D.H1tTQ0NL0f5GthaGxsZkBAAA46)  (https://info.cphi-chinaedm.com/x/?S7Y1Mf2fa2tsYG5p8D.H1tTQ0NL0f5GthaGxsZkBAAA46)online

Source Now at PharmaSources.com
E-Newsletter  November 2022 

Source Now at PharmaSources.com (https://www.pharmasources.com/?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)
Home (https://www.pharmasources.com/?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)
Products (https://www.pharmasources.com/products?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)
Suppliers (https://www.pharmasources.com/suppliers?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)
News (https://www.pharmasources.com/news?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)

Editor's Pick

The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in China (https://www.pharmasources.com/news/weekly-pharma-news-review-75931.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in ChinaThe NMPA revealed that Toludesvenlafaxine Hydrochloride Extended-Release Tablets (brand name: Ruoxinlin), a first-in-class drug developed by Luye Pharma, was approved for marketing for the treatment of depression...
Read More (https://www.pharmasources.com/news/weekly-pharma-news-review-75931.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)

Featured Suppliers

AVT (Shanghai) Pharmaceutical Tech CO. Ltd. (https://www.pharmasources.com/company-home/avt-shanghai-pharmaceutical-tech-co-ltd-userId-19081.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)AVT (Shanghai) Pharmaceutical Tech Co., Ltd.
Zhejiang Supor Pharmaceuticals Co., Ltd (https://www.pharmasources.com/company-home/zhejiang-supor-pharmaceuticals-co-ltd-userId-335.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)Zhejiang Supor Pharmaceuticals Co., Ltd

Featured Events

Endless Opportunities Await You at Virtual Expo Connect! (https://www.pharmasources.com/cphichinavec2022/landing?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)
Endless Opportunities Await You at Virtual Expo Connect!
21 November 2022 - 13 January 2023 Whether or not you plan to be at CPHI & PMEC in China, you can always join VEC for free. This year's show boasts a whole host of online features to suit every requirement so that you can extract maximum value from your trip by boosting your networking and visibility. Get it registered now!
Register For Free (https://www.pharmasources.com/cphichinavec2022/register?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)
Hot Products

BISMUTH SUBSALICYLATE (https://www.pharmasources.com/products/bismuth-subsalicylate-244143.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)BISMUTH SUBSALICYLATE
1,3-dibromo-5,5-dimethylhydantoin DBDMH Powder CAS NO.77-48-5 (https://www.pharmasources.com/products/1-3-dibromo-5-5-dimethylhydantoin-dbdmh-255823.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)1,3-dibromo-5,5-dimethylhydantoin DBDMH Powder
Silymarin (https://www.pharmasources.com/products/silymarin-284729.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)Silymarin

 

ValiDose  (https://www.pharmasources.com/products/validose-%7C-digital-health-%7C-personalized-284764.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)ValiDose | Digital Health | Personalized Precision Medicine
laboratory glassware washer (https://www.pharmasources.com/products/laboratory-glassware-washer-281592.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)laboratory glassware washer
LBF TURBOJET FLUID-BED GRANULATOR COATER (https://www.pharmasources.com/products/lbf-turbojet-fluid-bed-granulator-coater-284745.html?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)LBF TURBOJET FLUID-BED GRANULATOR COATER

Source More Products (https://www.pharmasources.com/products/?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)

Extend Your Business in Target Markets
 

Chinese Market Specific
Chinese Market Specific
Unlock tailor-made benefits from
Go-to-China Package
Go-To-China Package (https://efile.imsinoexpo.com/efile/CPhI/Ruby/Go to China package 2022 0808.pdf?utm_source=EDM&utm_medium=online&am%20p;utm_campaign=enedmPSenews1111)Global markets Extension
Global Markets Extension
Join now as a supplier member at PharmaSources.com
PharmaSources Membership Package (https://efile.imsinoexpo.com/efile/CPhI/Ruby/PharmaSources Sponsorship Package final.pdf?utm_source=EDM&utm_medium=online&am%20p;utm_campaign=enedmPSenews1111)
Get in Touch with Us (mailto:ruby.he at imsinoexpo.com?subject=Boost%20Pharma%20Business%20Online%20-%20Customized%C2%A0%20Digital%20Solutions)

Get in touch with us to know more customized  digital solutions
Contact Ms. Ruby He |  Email: ruby.he at imsinoexpo.com
  
----------------------------------------------------------------

Facebook (https://www.facebook.com/Pharmasources/?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)Twitter (https://twitter.com/Pharmachina365/?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)Linkedin (https://www.linkedin.com/company/13436110/admin/?utm_source=newsletter&utm_medium=email&utm_campaign=enedmPSenews1111)
Customer Service
+86-13621645194
PharmaSources at imsinoexpo.com (mailto:PharmaSources at imsinoexpo.com)
Scan this code to start a Telegram chat with PharmaSources
Telegram
Scan this code to start a WhatsApp chat with PharmaSources
WhatsApp

Unsubscribe (https://info.cphi-chinaedm.com/x/plugin/?pName=unsubscribe&MIDRID=S7Y1Mf2fa2tsYG5p8D.H1tTQ0NL0f5GthaGxsZkBAAA46&Z=-1822026223)
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.nottingham.ac.uk/pipermail/affymetrix-arabidopsis/attachments/20221111/8e52a30d/attachment-0001.html>